Chip stocks fall with Nvidia after data center rev disappointment
Investing.com - Oppenheimer maintained its Outperform rating and $75.00 price target on Revolution (NASDAQ:RVMD) following discussions with company management during a West Coast Biotech Bus Tour. The target sits well within the analyst range of $56-$88, with the stock currently trading at $37.01. According to InvestingPro data, RVMD maintains a strong financial position, holding more cash than debt on its balance sheet.
The research firm noted that Revolution recently guided for initial data from the daraxonrasib RASolute-302 study to be expected in 2026, with enrollment progressing well according to management.
Revolution confirmed that additional Phase 3 studies of daraxonrasib in first-line pancreatic ductal adenocarcinoma (PDAC) and in the adjuvant setting remain on track to begin this year, as previously announced.
The company continues to advance its non-small cell lung cancer (NSCLC) clinical development program and its work on RAS-selective inhibitors, according to Oppenheimer’s research note.
Oppenheimer highlighted that while daraxonrasib filing in second-line PDAC could occur in 2026, Revolution continues to make progress across its portfolio, with its strengthened balance sheet supporting ongoing clinical development and potential commercialization efforts. The company’s current ratio of 11.79 and minimal debt-to-capital ratio of 0.02 demonstrate its strong liquidity position to fund these initiatives.
In other recent news, Revolution Medicines reported its Q2 2025 earnings, which showed a larger-than-expected loss. The company posted an earnings per share (EPS) of -$1.31, missing the forecasted -$1.12. Additionally, Revolution Medicines did not meet revenue expectations, reporting $0 in revenue against an anticipated $30.59 million. In another development, Piper Sandler initiated coverage on Revolution with an Overweight rating and set a $75.00 price target. The research firm highlighted the potential of Revolution’s drug, daraxonrasib, in treating metastatic pancreatic ductal adenocarcinoma. These recent developments have drawn attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.